Dr. Eric Vigneault received his medical degree from the University of Montreal in 1992.In addition to completing his residency training in radiation oncology at the CHUQ Hôtel-Dieu de Quebec Hospital in 1997, Dr. Vigneault obtained a Master of Science degree in experimental medicine in 1996. He also completed a one year and a half fellowship in brachytherapy and three-dimensional external beam radiation therapy at the University of California San Francisco under the supervision of Dr. Mack Roach in 1998.He is involved in brachytherapy at both the provincial and national levels, as Chair of the Province of Quebec brachytherapy committee, and was president of the Canadian Brachytherapy Group from 2002 to 2006. Dr Vigneault was head of the Hotel-Dieu of Quebec Radiation-Oncology Department from 2003 to 2007. Dr Vigneault is actually the president elected of the Canadian Association of Radiation Oncology.Dr Vigneault is actively involved in a clinical research program investigating permanent and high-dose rate prostate brachytherapy. His other research interests include electronic portal imaging and intensity-modulated radiotherapy. He is involved in more than one hundred publication and presentations.
Dr. Shayegan is the Head of the Division of Urology at McMaster University. He holds the David Braley and Nancy Gordon Endowed Chair in Urology and practices as an academic urologic oncologist. He completed his medical school and residency training at the University of Toronto and then pursued a fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center in New York. His principle clinical and research interests are in the areas of prostate and bladder cancer.
Dr. Brita Danielson is a Radiation Oncologist at the Cross Cancer Institute in Edmonton, Associate Professor in the Department of Oncology, and Adjunct Associate Professor in the Department of Surgery at the University of Alberta. Dr. Danielson completed medical school at the University of Saskatchewan, and then undertook a Radiation Oncology residency at the University of Alberta. After residency, she completed a fellowship in Health Services Research at Queens University. She is the Alberta Genitourinary Tumor Team Leader, a role she has held since 2013, and recently completed an eight-year term as head of the Radiation Oncology GU Tumor Group at the Cross Cancer Institute. In 2016, she co-founded the Edmonton Prostate Interdisciplinary Cancer Clinic (EPICC), a collaboration between Radiation Oncology, Medical Oncology, and Urology, which provides care to patients with advanced prostate cancer. This clinic won the Health Quality Council of Alberta Patient Experience Award in 2019. Dr. Danielson is active in clinical trials for genitourinary and breast malignancies. Her research interests include access to care, quality of care, and palliative care, and she has authored or co-authored over thirty peer-reviewed publications. Nationally, she is a member of the Canadian Cancer Trials Group Audit and Monitoring Committee, as well as the Genitourinary Research Consortium Education Working Group.
Peter Black is a Urologic Oncologist at Vancouver General Hospital, a Research Scientist at the Vancouver Prostate Centre, and Professor in the Department of Urologic Sciences at the University of British Columbia. He received his undergraduate degree from the University of British Colombia in Vancouver and his medical degree from Johannes Gutenberg University in Mainz, Germany (1997). He completed his urologic training at the University of Washington in Seattle (2005) and fellowship in urologic oncology at M.D. Anderson Cancer Center in Houston, Texas (2008). Dr. Black has a clinical subspecialty interest in bladder and prostate cancer. He also maintains a grant-funded translational research program in urothelial carcinoma with a focus on mechanisms of resistance to chemotherapy and immunotherapy, and novel targeted therapies for bladder cancer. He has been involved in the design of multiple clinical trials in non-muscle invasive bladder cancer (NMIBC). He is study chair of a North American co-operative group trial (S1605) investigating the efficacy of immune checkpoint blockade in patients with BCG-unresponsive NMIBC. He is General Secretary of the International Bladder Cancer Network and editor-in-chief of the SIU Journal.
Ricardo Rendon (CHAIR)
Dr. Ricardo Rendon is an Urologic Oncologist and Associate Professor in the Department of Urology at Dalhousie University where he is the Director of Research and Chair of Clinical Trials. He is the Chair of the Genito-Urinary Cancer Site Team, Cancer Care Nova Scotia and a Senior Investigator at the Beatrice Hunter Cancer Research Institute. Dr. Rendon is currently the Scientific Chair of the Canadian Urological Association Scholarship Foundation and of the CUA Industry-sponsored Grant Programmes. Dr. Rendon has a Masters in Community Health Clinical Epidemiology. While his clinical practice focuses on all areas of urologic oncology, his research focuses on renal cell carcinoma and urothelial cell carcinoma. He has been particularly active in the development of clinical guidelines and other knowledge dissemination endeavours.
The Dr. Pouliot has carried out concomitant doctorates in medicine (M.D.) and Physiology-Endocrinology (Ph.D.) at Laval University. After completing a residency in Urology (F.R.C.S.C.), he did a post-doctoral fellowship in Urologic Oncology and molecular imaging at the University of California, Los Angeles (UCLA). He is a faculty and a urologic oncologist within Quebec City University Hospital Center since 2010. He is also an assistant professor in the Department of Surgery at Université Laval and holds a Prostate Cancer Canada/Movember Rising Star Awards. His clinical focus is on advanced and metastatic prostate and kidney cancers. His preclinical and clinical research interests include molecular imaging of recurrent and metastatic prostate cancer cells using transcriptional amplification systems and Positron Emission Tomography tracers such as Choline, PSMA binding peptides and Fluorodesoxyglucose.
Dr Tony Finelli is a urologic oncologist and surgeon investigator at the University Health Network (UHN) and Professor in the Department of Surgery at the University of Toronto. He is the Head of Urology, GU Site Lead at the Princess Margaret Cancer Center and the inaugural GU Oncology Lead for the province of Ontario. Dr Finelli is the Anna-Liisa Farquharson Chair in Kidney cancer research at the Princess Margaret Cancer Centre. He has built a program focused on correlative studies to improve our understanding of the natural history of localized kidney cancer. He is also actively involved in clinical trials and health services research. He has published more than 100 peer-reviewed manuscripts and holds peer-reviewed funding for his research. Dr Finelli’s clinical practice focuses on the management of prostate and kidney cancer with minimally invasive and robotic techniques. He has performed live surgery for instructional purposes in more than 10 countries. Dr Finelli is recognized internationally for his contributions to the growing body of literature regarding the management of small renal masses.
Dr. Kala Sridhar is an Associate Professor within the Department of Medicine, Division of Medical Oncology at the University of Toronto. She is head of the genitourinary cancers medical oncology site group at the Princess Margaret Hospital and treats primarily bladder, prostate and kidney cancers. She has an active research program in the area of bladder cancer, evaluating new therapies and imaging modalities; and is currently the international study chair of a National Cancer Institute of Canada (NCIC) phase 2 clinical trial. In 2011, she was recognized for her teaching excellence with a University of Toronto teaching award.
Dr. Tamim Niazi received his Doctor of Medicine and Master of Surgery (MDCM) designation from McGill University in 2001. He did his internship and residency at the McGill University Health Centre. During 2006 – 2007, he was the Clinical Trials Fellow at the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). He is currently an Assistant Professor of the Department of Oncology at McGill. His expertise include GU malignancies, mainly prostate cancer and upper GI such as gastric, pancreas and esophageal cancers. Dr. Niazi has designed and conducted numerous national Phase II and Phase III clinical trials with over 5 million dollars in research grants. In addition, Dr. Niazi has developed numerous innovative investigator-initiated clinical trials based on his own prior experience and preliminary data. Amongst others, Dr. Niazi’s research interests include combination trials of systemic therapy and targeted radiation therapy in prostate cancer with significant emphasis on correlative/biomarker components.
Urban Emmenegger is a Medical Oncologist at Odette Cancer Centre (Division of Medical Oncology) and Associate Scientist at Sunnybrook Research Institute (Biological Sciences Platform), both at Sunnybrook Health Sciences Centre (Toronto, ON, Canada). He is also Associate Professor in the Department of Medicine, and Associate Member of the Institute of Medical Science, both at the University of Toronto.
After having obtained his medical degree from the University of Bern/Switzerland in 1992, and following training in Experimental Medicine & Biology, Internal Medicine and Medical Oncology in Switzerland, in 2001 Urban Emmenegger joined the laboratory of Dr. Robert S. Kerbel (Sunnybrook Research Institute) to undertake postdoctoral training in tumor biology until 2008, with special emphasis on tumor angiogenesis and metronomic chemotherapy. In addition, he completed a clinical fellowship in Genitourinary Medical Oncology at the University of Toronto from 2005 to 2008.
Urban Emmenegger is specialized in the systemic treatment of advanced prostate cancer. Aside from clinical trial activities, he is interested in optimizing the real-world care of men with advanced prostate cancer, including managing bone metastases and bone health, preventing drug-drug interactions, studying treatment-induced sarcopenia, and improving the outcome of men with brain or liver metastases.